CN103328477B - 含有吡啶酮衍生物的药物组合物 - Google Patents

含有吡啶酮衍生物的药物组合物 Download PDF

Info

Publication number
CN103328477B
CN103328477B CN201280006741.XA CN201280006741A CN103328477B CN 103328477 B CN103328477 B CN 103328477B CN 201280006741 A CN201280006741 A CN 201280006741A CN 103328477 B CN103328477 B CN 103328477B
Authority
CN
China
Prior art keywords
oxo
oct
azabicyclic
niacinamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280006741.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103328477A (zh
Inventor
孟哲永
张龙九
车秀凤
申蕙园
郑灿美
车和伦
李银贞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CN103328477A publication Critical patent/CN103328477A/zh
Application granted granted Critical
Publication of CN103328477B publication Critical patent/CN103328477B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201280006741.XA 2011-01-28 2012-01-30 含有吡啶酮衍生物的药物组合物 Active CN103328477B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2011-0008960 2011-01-28
KR20110008960 2011-01-28
PCT/KR2012/000648 WO2012102580A1 (en) 2011-01-28 2012-01-30 Pharmaceutical composition comprising pyridone derivatives

Publications (2)

Publication Number Publication Date
CN103328477A CN103328477A (zh) 2013-09-25
CN103328477B true CN103328477B (zh) 2016-01-20

Family

ID=46581019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280006741.XA Active CN103328477B (zh) 2011-01-28 2012-01-30 含有吡啶酮衍生物的药物组合物

Country Status (8)

Country Link
US (1) US8716309B2 (enExample)
EP (1) EP2668186B1 (enExample)
JP (1) JP5921576B2 (enExample)
KR (1) KR101925971B1 (enExample)
CN (1) CN103328477B (enExample)
CA (1) CA2824467C (enExample)
ES (1) ES2634204T3 (enExample)
WO (1) WO2012102580A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
US10111867B2 (en) 2015-02-17 2018-10-30 Mapi Pharma Ltd. Process and intermediates for the preparation of perampanel
SI3433234T1 (sl) 2016-03-22 2022-01-31 Merck Sharp & Dohme Corp. Alosterični modulatorji nikotinskih acetilholinskih receptorjev
JP7360171B2 (ja) * 2017-07-31 2023-10-12 ワシントン・ユニバーシティ Ｂリンパ球活性の調節及び臓器保護のためのピルフェニドン誘導体
MY205690A (en) 2018-05-01 2024-11-06 Merck Sharp & Dohme Llc Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
CN109293507B (zh) * 2018-10-12 2020-12-18 河北科技大学 4-甲氧基甲烯基-2-烯戊二酸二甲酯的合成方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1345320A (zh) * 1999-01-29 2002-04-17 艾博特公司 用作烟碱性乙酰胆碱受体配体的二氮杂二环衍生物
CN1612876A (zh) * 2002-01-07 2005-05-04 法商沙诺费-辛芷拉保公司 5－(吡啶－3－基)－1－氮杂二环[3.2.1]辛烷衍生物,其制备及其治疗应用
WO2010056622A1 (en) * 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404138A (en) * 1982-06-22 1983-09-13 Warner-Lambert Company 3-[2-(Azabicyclo) ethyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin-5-ones
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
EP1453828A2 (en) * 2001-10-16 2004-09-08 AstraZeneca AB Azabicyclic compounds for the treatment of fibromyalgia syndrome
US8435762B2 (en) * 2008-10-09 2013-05-07 Howard Hughes Medical Institute Chimeric ligand-gated ion channels and methods of use thereof
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1345320A (zh) * 1999-01-29 2002-04-17 艾博特公司 用作烟碱性乙酰胆碱受体配体的二氮杂二环衍生物
CN1612876A (zh) * 2002-01-07 2005-05-04 法商沙诺费-辛芷拉保公司 5－(吡啶－3－基)－1－氮杂二环[3.2.1]辛烷衍生物,其制备及其治疗应用
WO2010056622A1 (en) * 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS

Also Published As

Publication number Publication date
EP2668186B1 (en) 2017-05-03
US8716309B2 (en) 2014-05-06
KR101925971B1 (ko) 2018-12-06
JP2014503599A (ja) 2014-02-13
US20130317059A1 (en) 2013-11-28
EP2668186A1 (en) 2013-12-04
CA2824467A1 (en) 2012-08-02
CN103328477A (zh) 2013-09-25
WO2012102580A1 (en) 2012-08-02
EP2668186A4 (en) 2014-03-19
KR20120087852A (ko) 2012-08-07
ES2634204T3 (es) 2017-09-27
CA2824467C (en) 2019-07-02
JP5921576B2 (ja) 2016-05-24

Similar Documents

Publication Publication Date Title
CN103328477B (zh) 含有吡啶酮衍生物的药物组合物
CA2467367C (en) Heteroaryl carboxamides
JP4497928B2 (ja) α７ニコチン性アセチルコリン受容体に対して親和性を有する１−アザビシクロＮ−ビアリールアミド
RU2323217C2 (ru) Новые хинуклидиновые производные и их применение
CN101784273B (zh) (2s，3r)‑n‑(2‑((3‑吡啶基)甲基)‑1‑氮杂双环[2.2.2]辛‑3‑基)苯并呋喃‑2‑甲酰胺、其新的盐形式和用法
SK6772002A3 (en) New use and novel n-azabicyclo-amide derivatives
US8691840B2 (en) N-biarylamides
KR102034305B1 (ko) 피리돈 유도체 및 이를 포함하는 약학적 조성물
CA2479097C (en) Amides of acetic and propionic acids
JP2007520525A (ja) 二量体のアザ環式化合物及びその使用
JP2007538046A (ja) 新規なアザビシクロアリール誘導体
CA2550844A1 (en) Nicotinic acetylcholine receptor ligands
HK1187336B (en) Pharmaceutical composition comprising pyridone derivatives
UA78812C2 (en) Quinuclidine derivatives and their use
HK1186469A (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant